{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-026723","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.234324+00:00","generated_at":"2026-05-31T22:10:01.987205+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024","bullets":["Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.","Company must evidence stockholders' equity of at least $2.5 million in the Form 10-Q.","Exploring additional equity financing to maintain compliance with Nasdaq equity requirement.","Risk of delisting if compliance not achieved; delisting would materially harm stock price and capital access."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-026723","json":"https://secwatch.observer/filing/0001493152-24-026723.json","markdown":"https://secwatch.observer/filing/0001493152-24-026723.md","text":"https://secwatch.observer/filing/0001493152-24-026723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/0001493152-24-026723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:10:01.987205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}